Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Oric Pharmaceuticals, Inc. (ORIC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "ORIC PHARMACEUTICALS, INC. CONDENSED BALANCE SHEETS Assets Current assets: Cash, cash equivalents and short-term investments $ 264,159 $ 206,272 Prepaid expenses and other current assets 4,199 4,185 Total current assets 268,358 210,457 Long-term investments 9,575 21,951 Property and equipment, net 3,250 3,253 Other assets 10,633 11,517 Total assets $ 291,816 $ 247,178 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 3,191 $ 1,320 Accrued liabilities 11,343 14,068 Total current liabilities 14,534 15,388 Other long-term liabilities 8,483 9,439 Total liabilities 23,017 24,827 Total stockholders' equity 268,799 222,351 Total liabilities and stockholders' equity $ 291,816 $ 247,178 ORIC PHARMACEUTICALS, INC. STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Mon..."
05/08/2023 8-K Quarterly results
Docs: "ORIC PHARMACEUTICALS, INC. CONDENSED BALANCE SHEETS Assets Current assets: Cash, cash equivalents and short-term investments $ 189,629 $ 206,272 Prepaid expenses and other current assets 3,535 4,185 Total current assets 193,164 210,457 Long-term investments 19,309 21,951 Property and equipment, net 3,112 3,253 Other assets 11,063 11,517 Total assets $ 226,648 $ 247,178 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 1,930 $ 1,320 Accrued liabilities 12,937 14,068 Total current liabilities 14,867 15,388 Other long-term liabilities 8,969 9,439 Total liabilities 23,836 24,827 Total stockholders' equity 202,812 222,351 Total liabilities and stockholders' equity $ 226,648 $ 247,178 ORIC PHARMACEUTICALS, INC. STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Mo..."
11/07/2022 8-K Quarterly results
Docs: "ORIC PHARMACEUTICALS, INC. CONDENSED BALANCE SHEETS Assets Current assets: Cash, cash equivalents and short-term investments $ 193,659 $ 236,979 Prepaid expenses and other current assets 5,026 3,543 Total current assets 198,685 240,522 Long-term investments 24,310 43,386 Property and equipment, net 3,049 2,413 Other assets 11,953 12,321 Total assets $ 237,997 $ 298,642 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 1,532 $ 1,886 Accrued liabilities 11,752 13,265 Total current liabilities 13,284 15,151 Other long-term liabilities 9,894 10,515 Total liabilities 23,178 25,666 Total stockholders' equity 214,819 272,976 Total liabilities and stockholders' equity $ 237,997 $ 298,642 ORIC PHARMACEUTICALS, INC. STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three M..."
08/11/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
11/08/2021 8-K Quarterly results
Docs: "ORIC PHARMACEUTICALS, INC. CONDENSED BALANCE SHEETS Assets Current assets: Cash, cash equivalents and short-term investments $ 289,519 $ 293,600 Prepaid expenses and other current assets 3,330 3,097 Total current assets 292,849 296,697 Investments, available-for-sale 6,956 — Property and equipment, net 1,825 1,981 Other assets 12,550 319 Total assets $ 314,180 $ 298,997 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 419 $ 757 Accrued liabilities 11,484 8,245 Total current liabilities 11,903 9,002 Other long-term liabilities 10,741 219 Total liabilities 22,644 9,221 Total stockholders' equity 291,536 289,776 Total liabilities and stockholders' equity $ 314,180 $ 298,997 ORIC PHARMACEUTICALS, INC. STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months En..."
08/10/2021 8-K Quarterly results
Docs: "ORIC PHARMACEUTICALS, INC. CONDENSED BALANCE SHEETS Assets Current assets: Cash, cash equivalents and short-term investments $ 261,068 $ 293,600 Prepaid expenses and other current assets 3,884 3,097 Total current assets 264,952 296,697 Property and equipment, net 1,828 1,981 Other assets 1,447 319 Total assets $ 268,227 $ 298,997 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 838 $ 757 Accrued liabilities 9,066 8,245 Total current liabilities 9,904 9,002 Other long-term liabilities — 219 Total liabilities 9,904 9,221 Total stockholders' equity 258,323 289,776 Total liabilities and stockholders' equity $ 268,227 $ 298,997 ORIC PHARMACEUTICALS, INC. STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2..."
05/06/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Licensed Exclusive Rights to EGFR/HER2 Exon 20 Inhibitor Program, ORIC-114: In October 2020, ORIC licensed from Voronoi, Inc. exclusive rights worldwide excluding the People’s Republic of China, Hong Kong, Macau and Taiwan for the development and commercialization of a potential best-in-class brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency against exon 20 insertion mutations. ORIC expects to file a Clinical Trial Application and initiate a global Phase 1/2 tumor-agnostic trial in genetically defined cancers for ORIC-114 in the second half of 2021. • Licensed Exclusive Worldwide Rights to PRC2 Inhibitor, ORIC-944: In August 2020, ORIC licensed fr..."
08/05/2020 8-K Quarterly results
05/20/2020 8-K Quarterly results
Docs: "First Patient Dosed in ORIC-101 Phase 1b Combination Trial for Prostate Cancer: In January 2020, ORIC announced the dosing of its first patient in a Phase 1b clinical trial being conducted under a collaboration with Astellas Pharma, Inc., to evaluate the combination of ORIC-101 with XTANDI® as a treatment for patients with metastatic prostate cancer that is progressing on enzalutamide. This marked ORIC’s second Phase 1b clinical trial of ORIC-101, following the initiation in 2019 of a Phase 1b trial of ORIC-101 in combination with Abraxane® in patients with solid tumors. • Preclinical Data on CD73 Inhibitor Program Presented at AACR: In April 2020, ORIC presented research that led to the discovery of ORIC-533, an orally bioavailable small molecule inhibitor of CD73, at the 2020 Amer..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy